continuous glucose monitor

By Jonah Comstock September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre. Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...
By Jonah Comstock June 22, 2018
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” FDA Commissioner Dr. Scott Gottlieb said in a statement. “These technologies allow patients to gain better control over their...
By Heather Mack May 5, 2017
Germantown, Maryland-based Senseonics may not be rolling in profits, but the company – which is working towards commercializing its implantable, long-term continuous glucose monitor – isn’t holding back on characterizing their position as strong. With expanded commercial launches in Germany and Sweden, plans for a presence in eight European countries by mid-2017, a CE Mark for their second...
By Jonah Comstock March 3, 2017
Implantable longterm continuous glucose monitor company Senseonics is in a better place than its financials would suggest. The company posted a net loss of $9.9 million last quarter, up from an $8.4 million loss in the year prior, and is planning to borrow about $5 million from the Oxford Silicon Valley Bank that it’s already $20 million in debt to. But Senseonic’s potentially game-changing...
By Jonah Comstock February 15, 2017
GluSense, an Israeli medical device company, announced an undisclosed investment from the JDRF T1D Fund, a recently launched VC philanthropy fund dedicated to funding early stage programs for Type 1 diabetes. GluSense is being incubated in the Rainbow Medical innovation house, a private investment company that seeds and grows medical device companies. The company’s first product in development is...
By Heather Mack December 7, 2016
Madison, Wisconsin-based Propeller Health, which offers a digitally-guided respiratory therapy platform, has teamed up with Medical International Research (MIR) to offer several of the Italian health technology company’s mobile and clinical spirometers alongside the Propeller system. The addition of sprirometers will give Propeller a more complete vision of the people using their platform, which...
By Jonah Comstock April 13, 2016
As their famous rallying cry states, the patients behind the Nightscout project for creating a do-it-yourself mobile technology for diabetes management are not waiting for approval from the FDA. But that doesn't mean they aren't seeking it, or that they haven't been in with the regulatory organization to make sure Nightscout is as safe as it can be. In a new editorial published in the...
By Aditi Pai August 25, 2015
The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article incorrectly stated the device had a 510(k) clearance when in fact it had a PMA approval. Unlike the company's previous connected CGM devices, the G5 Mobile CGM System has Bluetooth built right in to the...
By Aditi Pai August 12, 2015
Germantown, Maryland-based continuous glucose monitor device maker Senseonics raised $10 million, according to an SEC filing. The company has not yet responded to a request for comment. Existing investors include Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, and New Enterprise Associates. This brings the company’s total funding to at least $94 million to date....
By Jonah Comstock February 9, 2015
Dexcom's Apple Watch app will be ready to go when the device launches in April, the company told the Wall Street Journal. The app, which will not need to seek pre-market approval from the FDA thanks to a recent reclassification, will allow the Apple Watch to serve as a secondary display device for the Dexcom G4 (and upcoming G5) continuous glucose monitor system. The primary display will remain...
http://steroid-pharm.com

https://steroid-pharm.com

https://steroid-pharm.com